— Titan Pharmaceuticals (NASDAQ: TTNP) reported Q3 2019 loss of $0.18 per share, vs. $0.21 expected.
— Revenues fell 47% to approx. $0.9 million, vs. $0.7 million expected.
— Product revenues totaled approx. $0.2 million.
— Grant revenues totaled approx. $0.8 million.
— R&D expenses amounted to approx. $1.6 million.
— TTNP shares gained 1% immediately following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Key highlights from Pfizer’s (PFE) Q1 2025 earnings results
Pfizer Inc. (NYSE: PFE) reported its first quarter 2025 earnings results today. Revenues decreased 8% year-over-year to $13.7 billion. GAAP net income decreased 5% to $2.96 billion, or $0.52 per
PYPL Earnings: PayPal reports higher Q1 2025 revenue and profit
PayPal Holdings Inc. (NASDAQ: PYPL) on Tuesday reported a modest increase in revenue for the first quarter of 2025 when the payment service giant's adjusted earnings rose by double digits.
General Motors (GM) Q1 2025 revenue and adj. earnings beat estimates
Auto giant General Motors (NYSE: GM) on Tuesday announced financial results for the first quarter of 2025, reporting an increase in revenue and adjusted profit. The results also topped expectations.
